Kalaris Therapeutics Inc. (NASDAQ: KLRS) announced it will present clinical data from its Phase 1 study of TH103 at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE